Visit Type (Check one)

Size: px
Start display at page:

Download "Visit Type (Check one)"

Transcription

1 Page 1 of 14 OHFV21.01 MULE: Page 1 Visit Type (Check one) Visit prior to 078 month visit enter visit window 0 Semi-Annual: Annual: 078 mo. 090 mo. 102 mo. 114 mo. 126 mo. 138 mo. 150 mo. 162 mo. 084 mo. 096 mo. 108 mo. 120 mo. 132 mo. 144 mo. 156 mo. 168 mo. 1. If OHTS II consent form is completed at this visit, check here: Consent and complete a Transition Visit Status (TV) form and send with this FV 2. Was information on this form obtained from a non-ohts office? No Yes If yes, enter OHTS PI or CC initials completing this form:

2 Page 2 of 14 OHFV21.02 MULE: Non Ocular Meds 1. Is the patient currently taking any of the following categories of medication? (Consult PDR or OHTS Medication List in the MOP Ch. 11 if necessary) a. Systemic Beta-blocker... Yes No b. Calcium Channel Blocker... Yes No c. Statin... Yes No d. Anti-Depressant... Yes No e. Ocular Corticosteroid... Yes No f. Systemic Corticosteroid... Yes No g. Nasal Steroid... Yes No h. Bronchial Inhaled Steroid... Yes No i. Estrogen or Progesterone for hormone replacement therapy... Yes No Certification (CC or PI)

3 Page 3 of 14 OHFV21.03 Clinic Coordinator/Investigator Instructions: Ask for ocular and medical history since the date of patient s last regularly scheduled follow-up visit (FV). MULE: Ocular History Ocular History 1. Have you had eye surgery since (state last FV date)? Yes No (If yes, complete Adverse Event Form and repeat Pachymeter measurement and complete PY form) 2. If yes, check appropriate boxes: a. Penetrating keratoplasty... Yes Yes b. Retinal detachment repair... Yes Yes c. Retinal tear... Yes Yes d. Laser trabeculoplasty... Yes Yes e. Laser iridotomy... Yes Yes f. Combined cataract/filtering surgery... Yes Yes g. Filtering surgery... Yes Yes h. Cataract extraction... Yes Yes i. Photo refractive surgery (e.g. LASIK)... Yes Yes j. Lid surgery... Yes Yes k. Other (describe):... Yes Yes 3. Are you currently using eyedrops to lower the pressure in your eyes?... Yes No Certification (CC or PI)

4 Page 4 of 14 OHFV21.04 MULE: Medical History Medical History 1. Have you seen a doctor since (state last FV date)?... Yes No If yes, for what problem(s)? 2. Have any new health problems been diagnosed... Yes No since (state last FV date)? (If yes, complete Adverse Event Form) If yes, check appropriate boxes: a. High blood pressure (hypertension)... Yes b. Low blood pressure (hypotension)... Yes c. Diabetes, or sugar in the blood... Yes d. Asthma... Yes e. Chronic lung disease... Yes f. Stroke... Yes g. Cancer... Yes h. Heart disease... Yes i. Migraine headaches... Yes j. Depression or other mental health conditions... Yes k. Other conditions: Yes 3. Has a previously reported medical condition worsened... Yes No requiring a change in therapy since (state last FV date)? (If yes, complete Adverse Event Form) If yes, check appropriate boxes: a. High blood pressure (hypertension)... Yes b. Low blood pressure (hypotension)... Yes c. Diabetes, or sugar in the blood... Yes d. Asthma... Yes e. Chronic lung disease... Yes f. Stroke... Yes g. Cancer... Yes h. Heart disease... Yes i. Migraine headaches... Yes j. Depression or other mental health conditions... Yes k. Other conditions: Yes 4. Have you had an inpatient hospitalization since... Yes No (state last FV date)? (If yes, complete Adverse Event Form) If yes, describe

5 Page 5 of 14 OHFV21.05 MULE: Medical History Medical History (continued) 5. Have you had any surgery other than ocular surgery... Yes No since (state last FV date)? (If yes, complete Adverse Event Form) If yes, describe 6. Have you missed work or been unable to perform your usual activities because of illness or accident since (state last FV date)?... Yes No If yes, describe (May require an Adverse Event Form) 7. (Ask Male Participants about prostate cancer at annual visits) a. Have you ever been told that you have prostate cancer?... Yes No If yes, what year were you first told that you had prostate cancer? b. Have you ever received treatment for prostate cancer either medication, radiation, or surgery? a. Medication... Yes b. Radiation... Yes c. Surgery... Yes History reviewed by Investigator Certification

6 Page 6 of 14 OHFV21.06 MULE: Blood Pressure Blood Pressure 1. 1st Blood Pressure Measurement Systolic/Diastolic: SYS /DIA Pulse 2. Reason for not having Blood Pressure or Pulse Data (check all that apply): a. Monitor inoperative... Yes b. Cuff too small... Yes c. Blood pressure greater than 280 mmhg... Yes d. Pulse too low... Yes e. Pulse too high... Yes f. Movement... Yes g. Other conditions... Yes 3. 2nd Blood Pressure Measurement Systolic/Diastolic: SYS /DIA Pulse 4. Reason for not having Blood Pressure or Pulse Data (check all that apply): a. Monitor inoperative... Yes b. Cuff too small... Yes c. Blood pressure greater than 280 mmhg... Yes d. Pulse too low... Yes e. Pulse too high... Yes f. Movement... Yes g. Other conditions... Yes Blood Pressure taken by

7 Page 7 of 14 6 OHFV21.07 MULE: Refraction Refraction (at 78, 90, 102, 114, 126, 138, 150, 162 mos.) 1. Refraction 2. Refraction Plus Minus. Plus Minus. Plus Minus. x Plus Minus. x Refraction taken by MULE: Snellen V.A. Snellen Visual Acuity Or choose 1. Snellen visual acuity / CF HM LP NLP 2. Snellen visual acuity / CF HM LP NLP Snellen acuity taken by If Snellen visual acuity is worse than 20/200, ETDRS VA is not required in that eye.

8 Page 8 of 14 OHFV21.08 MULE: ETDRS ETDRS Best Corrected Visual Acuity (at 78, 90, 102, 114, 126, 138, 150, 162 mos.) ETDRS visual acuity - 1. Testing distance in meters (check box) 4.0m 3.2m 2.5m 2.0m 2. Total number correct: ETDRS visual acuity - 3. Testing distance in meters (check box) 4.0m 3.2m 2.5m 2.0m 4. Total number correct: ETDRS acuity taken by MULE: Pelli-Robson Pelli-Robson Contrast Sensitivity (at 78, 90, 102, 114, 126, 138, 150, 162 mos.) Pelli-Robson - 1. Score from worksheet: Pelli-Robson - 2. Score from worksheet: Pelli-Robson taken by

9 Page 9 of 14 OHFV21.09 IOP is measured by two people - the OPERATOR aligns the mires - the RECORDER reads the dial MULE: IOP Determination IOP Determination 1. Date IOP completed / / 2. Time of measurement : am pm 3. 1st IOP mm Hg mm Hg 4. 2nd IOP mm Hg mm Hg Are the 1st and 2nd IOP determinations less than or equal to 2 mm Hg apart? Yes: Enter their average on line 6. No: Take a 3rd reading and enter on line rd IOP mm Hg mm Hg If a 3rd IOP is taken, enter the median (middle value) of 1st, 2nd, and 3rd IOP on line IOP Result mm Hg mm Hg Round to nearest whole number Round up when decimal is.5 or greater 7. Patient s Study Goal mm Hg mm Hg 8. Check here if using a Non-Goldmann Tonometer... Operator Certification Recorder Certification 9. Is IOP goal met?... Yes No Yes No 10. If IOP goal is met, you have three options: a. No change in treatment regimen... b. Change treatment regimen due to symptoms... Complete Adverse Event Form c. Change treatment regimen for other reason(s)... describe: 11. If IOP goal is not met, you have six options: a. Instruct patient to use eye drops on schedule... Schedule return visit in 4 ± 2 weeks b. Change medication this visit... Schedule return visit in 4 ± 2 weeks c. Change medication due to symptoms... Schedule return visit in 4 ± 2 weeks Complete Adverse Event Form d. No change, already on maximum meds... e. No change, patient declines medications... f. Other action, describe:

10 MULE: Ocular Examination Summary of Ocular Examination Page 10 of 14 OHFV Date ocular exam completed / / 2. External examination: Normal Abnormal, describe: 3. Slit lamp examination: Normal Abnormal, describe: Normal Abnormal, describe: Normal Abnormal, describe: 4. Presence of pseudoexfoliation: (At annual dilated exam) No Yes No Yes 5. Gonioscopy: (Complete at 90, 114, 138, 162 month visits) Open angles Open angles Narrow angles (Angle slit Narrow angles (Angle slit or Grade 1 in more than or Grade 1 in more than 25% of the circumference) 25% of the circumference) Appositional (Angle closure Appositional (Angle closure over more than 25% of the over more than 25% of the circumference) circumference) Closure (PAS over more than Closure (PAS over more than 25% of the circumference) 25% of the circumference) 6. Direct ophthalmoscopic examination: Normal Abnormal (other than disc hemorrhage), describe: Normal Abnormal (other than disc hemorrhage), describe:

11 MULE: Ocular Examination Summary of Ocular Examination (continued) Page 11 of 14 OHFV If disc hemorrhage: (check here) Yes (list clock hours): Yes (list clock hours): : to : : to : 8. Investigator answers the following question: Has patient developed any condition(s) that can cause visual field loss (pituitary lesion, demyelinating disease, pseudotumor, etc.)?... Yes If yes, describe No Investigator Certification:

12 Track medications prescribed to patient (6 month supply) Enter quantity of zero if no medications dispensed at this visit MULE: Ocular Meds Ocular Medication Prescribed Ocular Medication Dispensed # of Bottle if NOT Dosage Bottles Size from OHTS (# times daily) supply 1. Beta-Blockers Dispensed (ml) optional Betagan 0.25% Betagan 0.50% Betimol 0.50% Betoptic S 0.25% Carteolol 1.0% Istalol 0.5% OptiPranolol 0.30% Timoptic 0.25% Timoptic XE 0.25% Timoptic 0.50% Timoptic XE 0.50% Timoptic PsF 0.25% Timoptic PsF 0.50% Page 12 of 14 OHFV Epinephrine/Dipivefrin Propine 0.1% 3. Alpha 2 Agonists Alphagan-P 0.1% Alphagan-P 0.15% Iopidine 0.5% 4. Topical Carbonic Anhydrase Inhibitor Azopt 1.0% Trusopt 2.0% 5. Prostaglandin Analogue Lumigan 0.03% Travatan 0.004% Travatan-Z 0.004% Xalatan 0.005% 6. Combination Therapy (Beta-Blocker/Topical Carbonic Anhydrase Inhibitor) Cosopt

13 Track medications prescribed to patient (6 month supply) Enter quantity of zero if no medications Ocular Medication Prescribed dispensed at this visit MULE: Ocular Meds Ocular Medication Dispensed Page 13 of 14 OHFV21.13 # of Bottle if NOT Dosage Bottles Size from OHTS (# times daily) 1. Miotics Dispensed (ml) supply optional Carbachol 1.50% Pilocarpine 1.0% Pilocarpine 2.0% Pilocarpine 4.0% Pilocarpine 6.0% Pilopine gel 4.0% 2. Other Ocular Hypotensive Describe: 3. If medication was not prescribed for one or both eyes check the following: Eye(s) Reason (Check all that apply) None One-Eyed Trial None Adverse Event (Complete AE Form) None OU Treatment Change approved IOP goal met without medication Patient declines medication (Check reasons): Side effects Inconvenient Unable to self-dispense eye drops Patient thinks medications are not necessary Patient feels he/she is already taking enough medications Personal philosophy Other, describe: POAG Endpoint Reached Other reason, describe: Investigator Certification

14 Page 14 of 14 OHFV21.14 MULE: V.F. Series Humphrey 30-2 Visual Field Series Use OHTS certified perimeter only Ship diskette and printout to VFRC ASAP If 1st field is unreliable, repeat the field in 1 hour or schedule a visit in 4 ± 2 weeks using the Unscheduled Visit: UN form 1. For which eye(s) were Visual Fields taken for OU Neither this patient? 2. If taken, enter dates / / / / 3. If one or more eyes not done, explain: MULE: Optic Disc Photo Stereo Optic Disc Photography (Required at ANNUAL visits) Send checklist and photos to RC within 1 week If photos are missed, send checklist to RC (Reminder: Take photos as soon as possible) 1. For which eye(s) were Optic Disc Photos taken for this patient? OU Neither 2. If taken, enter dates / / / / 3. If one or more eyes not done, explain: If patient signed OHTS II consent, complete a new Transition Visit Status (TV) form. Copyright Ocular Hypertension Treatment Study All rights reserved

Reason for Unscheduled Visit

Reason for Unscheduled Visit Page 1 of 7 OHUN16.01 MULE: UNREASONS Reason for Unscheduled Visit * On any given page, any section started should be completed. Check all that apply: 1. Confirmation of IOP... Complete Snellen, IOP, Ocular

More information

Snellen VA 2 IOP 3 Ocular Examination * Only dilate if repeat photos required

Snellen VA 2 IOP 3 Ocular Examination * Only dilate if repeat photos required Page 1 of 7 Visit Date: Check Completed Modules Page Number Snellen VA 2 IOP 3 Ocular Examination * Only dilate if repeat photos required Humphrey VFs (if required) 5 Disc Photography (if required) 6 OCT

More information

OHTS Baseline/Randomization Visit: BR

OHTS Baseline/Randomization Visit: BR Page 1 of 5 2/28/5 OHBR02.00 Coordinating Center use only Rec d... Log d... Chk d... Entr d... Checklist Check when completed Before exam, patient first completes SF-36 Quality of Life Before exam, patient

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 May 2008

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 May 2008 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 May 2008 COSOPT 20 mg/5 mg/ml, eye drops, solution in single dose container Box of 60 0.2 ml single dose containers

More information

Collaboration in the care of glaucoma patients and glaucoma suspects. Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012

Collaboration in the care of glaucoma patients and glaucoma suspects. Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012 Collaboration in the care of glaucoma patients and glaucoma suspects Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012 Goals of Collaboration Patient-centred and evidence based approach Timely access

More information

Treatments for Open-Angle Glaucoma. A Review of the Research for Adults

Treatments for Open-Angle Glaucoma. A Review of the Research for Adults Treatments for Open-Angle Glaucoma A Review of the Research for Adults Is This Information Right for Me? Yes, this information is for you if: Your eye doctor has said that you have open-angle glaucoma,

More information

Vision Health: Conditions, Disorders & Treatments GLAUCOMA

Vision Health: Conditions, Disorders & Treatments GLAUCOMA Vision Health: Conditions, Disorders & Treatments GLAUCOMA Glaucoma is a disease of the optic nerve, which transmits the images you see from the eye to the brain. The optic nerve is made up of many nerve

More information

Glaucoma Clinical Update. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

Glaucoma Clinical Update. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Glaucoma Clinical Update Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Objectives Understand the different categories of glaucoma Recognize the symptoms and signs of open angle and angle-closure

More information

5/12/2014. Lynn E. Lawrence, CPOT, ABOC, COA

5/12/2014. Lynn E. Lawrence, CPOT, ABOC, COA Lynn E. Lawrence, CPOT, ABOC, COA Glaucoma is an optic neuropathy characterized by a loss of ganglion cells and their axons, in the RNFL. The loss of retinal ganglion cells in glaucoma is irreversible

More information

Financial Disclosure. Prostaglandin Analogs (PGs) The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy

Financial Disclosure. Prostaglandin Analogs (PGs) The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy Danica J. Marrelli, OD, FAAO University of Houston College of Optometry Financial Disclosure I have received I have received speaking

More information

GLAUCOMA (2006) PHILIPPINE GLAUCOMA SOCIETY

GLAUCOMA (2006) PHILIPPINE GLAUCOMA SOCIETY GLAUCOMA (2006) PHILIPPINE GLAUCOMA SOCIETY CPM 9 TH EDITION Philippine Glaucoma Society (PGS) Correspondence to: Eye Referral Center, T. M. Kalaw Street, Ermita, Manila Telephone: 524-7119/525-9360 Mobile:

More information

Goals. Glaucoma PARA PEARL TO DO. Vision Loss with Glaucoma

Goals. Glaucoma PARA PEARL TO DO. Vision Loss with Glaucoma Glaucoma Janet R. Fett, OD Drs. Kincaid, Fett and Tharp So Sioux City, NE eyewear21@hotmail.com Goals Understand Glaucoma Disease process Understand how your data (objective and subjective) assists in

More information

BrightFocus Foundation is the new name for American Health Assistance Foundation.

BrightFocus Foundation is the new name for American Health Assistance Foundation. In this section, you will find the following: Glaucoma Medications Laser Therapies Conventional Surgical Procedures In the second section, you will find information on how to search for potential treatments

More information

East and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults

East and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults East and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults Introduction Glaucoma is a group of eye diseases causing optic nerve damage. In most cases

More information

PRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA

PRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA PRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA DR. RAVI THOMAS, DR. RAJUL PARIKH, DR. SHEFALI PARIKH IJO MAY 2008 PRESENTER AT JDOS : DR. RAHUL SHUKLA T.N. SHUKLA EYE HOSPITAL TERMINOLOGY POAG: PRIMARY

More information

Managing the Patient with POAG

Managing the Patient with POAG Managing the Patient with POAG Vision Institute Annual Fall Conference Mitchell W. Dul, OD, MS, FAAO mdul@sunyopt.edu Richard J. Madonna, MA, OD, FAAO rmadonna@sunyopt.edu Ocular Hypertension (OHT) Most

More information

Technicians & Nurses Program

Technicians & Nurses Program ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans I have none Sunday, May 8, 2016, 10:30-11:30am Amy Jost, BS, COMT, CCRC Cincinnati Eye Institute Identify the tech

More information

South East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension Treatment Pathway

South East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension Treatment Pathway Proceed to 2 nd line treatment if further reduction in IOP required and there is good response to PGAs or (& no South East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension

More information

Get a grip on your glaucoma Booklet 1

Get a grip on your glaucoma Booklet 1 Information for Patients Glaucoma services Welcome! Get a grip on your glaucoma Booklet 1 Group-based Glaucoma information Course Session 1 What happens in session 1? Finding out what questions you have

More information

Class Update with New Drug Evaluation: Glaucoma Drugs

Class Update with New Drug Evaluation: Glaucoma Drugs Class Update with New Drug Evaluation: Glaucoma Drugs Date of Review: May 2018 Date of Last Review: January 2015 End Date of Literature Search: 02/26/2018 Generic Name: latanoprostene bunod Brand Name

More information

Glaucoma. How is Glaucoma Diagnosed? Glaucoma Testing

Glaucoma. How is Glaucoma Diagnosed? Glaucoma Testing Glaucoma How is Glaucoma Diagnosed? Glaucoma Testing There is no single test for glaucoma. The diagnosis is made by evaluating the patient from a number of perspectives, using specialized instruments.

More information

Glaucoma. Glaucoma. Optic Disc Cupping

Glaucoma. Glaucoma. Optic Disc Cupping Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville

More information

Class Update with New Drug Evaluation: Glaucoma Drugs

Class Update with New Drug Evaluation: Glaucoma Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

DISCLOSURE: What to do? 2/22/2016

DISCLOSURE: What to do? 2/22/2016 DISCLOSURE: Dr. Joseph Sowka is a member of the Speakers Bureau for Alcon Laboratories, and Carl Zeiss Meditec. He is on the advisory boards for Alcon, Zeiss, and Allergan. He is a consultant for Alcon.

More information

Intro to Glaucoma/2006

Intro to Glaucoma/2006 Intro to Glaucoma/2006 Managing Patients with Glaucoma is Exciting Interesting Challenging But can often be frustrating! Clinical Challenges To identify patients with risk factors for possible glaucoma.

More information

1/16/2018. Brett J. Teague, M.D. Big Country Eye Center Abilene, Texas

1/16/2018. Brett J. Teague, M.D. Big Country Eye Center Abilene, Texas Brett J. Teague, M.D. Big Country Eye Center Abilene, Texas I developed the course material/information independently No relevant financial relationship exists by anyone in control of presentation content

More information

Long Term Care Formulary RS 14. RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5

Long Term Care Formulary RS 14. RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5 RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5 PREAMBLE Significance: Glaucoma occurs in 1-2% of white people aged over 40 years, rising to 5% at 70 years and exponentially with advancing

More information

Nate Lighthizer, O.D., F.A.A.O. Assistant Professor, NSUOCO Assistant Dean, Clinical Care Services Director of CE Chief of Specialty Care Clinics

Nate Lighthizer, O.D., F.A.A.O. Assistant Professor, NSUOCO Assistant Dean, Clinical Care Services Director of CE Chief of Specialty Care Clinics Nate Lighthizer, O.D., F.A.A.O. Assistant Professor, NSUOCO Assistant Dean, Clinical Care Services Director of CE Chief of Specialty Care Clinics Chief of Electrodiagnostics Clinic lighthiz@nsuok.edu YAG

More information

KEY MESSAGES. Details of the evidence supporting these recommendations can be found in the above CPG, available on the following websites:

KEY MESSAGES. Details of the evidence supporting these recommendations can be found in the above CPG, available on the following websites: QUICK REFERENCE FOR HEALTHCARE PROVIDERS KEY MESSAGES 1. Glaucoma is a chronic eye disease that damages the optic nerve, & can result in serious vision loss and irreversible blindness. 2. Glaucoma diagnosis

More information

4/06/2013. Medication Observation POAG. Proportion. Native American 0.1% 0.4%

4/06/2013. Medication Observation POAG. Proportion. Native American 0.1% 0.4% Clinical Research in Glaucoma: Putting Science into Practice J. James Thimons, O.D., FAAO Chairman, National Glaucoma Society www.nationalglaucomasociety.org Ocular Hypertension Treatment Study (OHTS)

More information

53 year old woman attends your practice for routine exam. She has no past medical history or family history of note.

53 year old woman attends your practice for routine exam. She has no past medical history or family history of note. Case 1 Normal Tension Glaucoma 53 year old woman attends your practice for routine exam. She has no past medical history or family history of note. Table 1. Right Eye Left Eye Visual acuity 6/6 6/6 Ishihara

More information

Efficacy of latanoprost in management of chronic angle closure glaucoma. Kumar S 1, Malik A 2 Singh M 3, Sood S 4. Abstract

Efficacy of latanoprost in management of chronic angle closure glaucoma. Kumar S 1, Malik A 2 Singh M 3, Sood S 4. Abstract Original article Efficacy of latanoprost in management of chronic angle closure glaucoma Kumar S 1, Malik A 2 Singh M 3, Sood S 4 1 Associate Professor, 2 Assistant Professor, 4 Professor, Department of

More information

Volume 9; Number 6 May 2015 PRESCRIBING FOR CHRONIC OPEN ANGLE GLAUCOMA (COAG) AND OCULAR HYPERTENSION (OHT)

Volume 9; Number 6 May 2015 PRESCRIBING FOR CHRONIC OPEN ANGLE GLAUCOMA (COAG) AND OCULAR HYPERTENSION (OHT) Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire

More information

Effect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial

Effect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial European Journal of Ophthalmology / Vol. 13 no. 7, 2003 / pp. 611-615 Effect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial S.A. GANDOLFI, L. CIMINO, P.

More information

Is There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function?

Is There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function? Is There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function? Supported by the National Eye Institute (EY 09307, EY 09341) National Center on Minority

More information

GLAUCOMA SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES

GLAUCOMA SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES Introduction These are summary benchmarks for the Academy s Preferred Practice Pattern (PPP) guidelines. The Preferred Practice Pattern series

More information

Dr. Litwak is on the speaker bureau and advisory panel for Alcon and Zeiss Meditek

Dr. Litwak is on the speaker bureau and advisory panel for Alcon and Zeiss Meditek My Favorite Cases Anthony B. Litwak,OD, FAAO VA Medical Center Baltimore, Maryland Dr. Litwak is on the speaker bureau and advisory panel for Alcon and Zeiss Meditek Case LA 62 yobf +HTN, + DM POH told

More information

OCULAR PHARMACOLOGY GLAUCOMA. increased intraocular pressure. normally mm Hg. when to Tx no fixed level.

OCULAR PHARMACOLOGY GLAUCOMA. increased intraocular pressure. normally mm Hg. when to Tx no fixed level. OCULAR PHARMACOLOGY GLAUCOMA increased intraocular pressure normally 12 20 mm Hg. when to Tx no fixed level. literature sets ~21 mm Hg as upper limit of normal. some safe at 30 mm Hg some may have damage

More information

THE CHRONIC GLAUCOMAS

THE CHRONIC GLAUCOMAS THE CHRONIC GLAUCOMAS WHAT IS GLAUCOMA? People with glaucoma have lost some of their field of all round vision. It is often the edge or periphery that is lost. That is why the condition can be missed until

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Guidelines for the medical treatment of chronic open angle glaucoma and ocular hypertension Summary: DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Diagnosis and management of ocular hypertension (OHT)

More information

WORLD GLAUCOMA WEEK What is Glaucoma? Can I develop glaucoma if I have increased eye pressure?

WORLD GLAUCOMA WEEK What is Glaucoma? Can I develop glaucoma if I have increased eye pressure? WORLD GLAUCOMA WEEK What is Glaucoma? Glaucoma is a group of diseases that damage the optic nerve and can result in gradual vision loss and blindness. However, with early detection and treatment, you can

More information

Understanding And Living With Glaucoma

Understanding And Living With Glaucoma Understanding And Living With Glaucoma Samantha hopes future generations won t have to live with glaucoma. Dr. Horner s breakthrough research could mean they won t have to. Supported by an educational

More information

Glaucoma: diagnosis and management (large print version)

Glaucoma: diagnosis and management (large print version) Glaucoma: diagnosis and management (large print version) 1 November 2017 Recommendations People have the right to be involved in discussions and make informed decisions about their care, as described in

More information

Glaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough?

Glaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough? Glaucoma Disease Progression Role of Intra Ocular Pressure Is Good Enough, Low Enough? Glaucoma Diseases Progression Key Considerations Good number of patients may be diagnosed only after some damage the

More information

NEPTUNE RED BANK BRICK

NEPTUNE RED BANK BRICK NEPTUNE RED BANK BRICK Diabetes & The Eye Diabetics are more likely to develop Cataracts at a younger age. Diabetics are twice as likely to develop Glaucoma when compared to non-diabetics. The primary

More information

Clinical Research in Glaucoma

Clinical Research in Glaucoma Clinical Research in Glaucoma J. James Thimons, O.D., FAAO Chairman, National Glaucoma Society www.nationalglaucomasociety.org Ocular Hypertension Treatment Study (OHTS) Primary Goals Evaluate the safety

More information

M Diestelhorst, L-I Larsson,* for The European Latanoprost Fixed Combination Study Group...

M Diestelhorst, L-I Larsson,* for The European Latanoprost Fixed Combination Study Group... 199 SCIENTIFIC REPORT A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension

More information

Abbreviated Update: Ophthalmic Glaucoma Agents

Abbreviated Update: Ophthalmic Glaucoma Agents Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Abbreviated Update: Ophthalmic Glaucoma Agents Month/Year

More information

@HUHEYE in Haiti 2018

@HUHEYE in Haiti 2018 @HUHEYE in Haiti 2018 Eye Evaluation and Common Eye Diseases Leslie S. Jones, MD Associate Professor and Interim Chair Residency Program Director Glaucoma Services Director Department of Ophthalmology

More information

1/31/2018. Course Objectives. Diagnostic Testing. Optic Nerve Damage ANATOMY AND PHYSIOLOGY OF A GLAUCOMA WORK-UP/TONOMETRY TECHNICIAN: -SDP

1/31/2018. Course Objectives. Diagnostic Testing. Optic Nerve Damage ANATOMY AND PHYSIOLOGY OF A GLAUCOMA WORK-UP/TONOMETRY TECHNICIAN: -SDP ANATOMY AND PHYSIOLOGY OF A GLAUCOMA WORK-UP/TONOMETRY KNOW THE DISEASE PROCESS TECHNICIAN: EXPLAIN PROCESS OF EXAMINATION Presenters: Dana McMahan, COA Nicole Smith, COA Engage with patient s, help alleviate

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION Contents METHODS... 2 Inclusion and exclusion criteria... 2 Supplementary table S1... 2 Assessment of abnormal ocular signs and symptoms... 3 Supplementary table S2... 3 Ocular

More information

Divakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16

Divakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16 Divakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16 Pathophysiology of glaucoma Consider risk factors of glaucoma Understand the side effects of glaucoma medications Diagnostic testing Leading cause

More information

Closed Angle Glaucoma Or Narrow Angle Glaucoma. What s is a closed angle type of glaucoma,

Closed Angle Glaucoma Or Narrow Angle Glaucoma. What s is a closed angle type of glaucoma, Closed Angle Glaucoma Or Narrow Angle Glaucoma What s is a closed angle type of glaucoma, This is where the iris is found to be blocking the drainage of the eye through the trabecular meshwork. The eye

More information

THE CHRONIC GLAUCOMAS

THE CHRONIC GLAUCOMAS THE CHRONIC GLAUCOMAS WHAT IS GLAUCOMA People with glaucoma have lost some of their field of all round vision. It is often the edge or periphery that is lost. That is why the condition can be missed until

More information

IOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose)

IOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose) This overview of 2% eye drops was presented by Dr. Ravin N. Das, at Hotel Satya Ashoka, on 19-6-2004 in place of Dr. H. S. Ray due to unforseen circumstances. This dinner meeting was sponsored by Cipla

More information

8 USE IN SPECIFIC POPULATIONS Patients with Open-Angle Glaucoma or Ocular Hypertension

8 USE IN SPECIFIC POPULATIONS Patients with Open-Angle Glaucoma or Ocular Hypertension 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Isopto Carpine safely and effectively. See full prescribing information for Isopto Carpine. Isopto

More information

Class Update: Ophthalmic Glaucoma Agents

Class Update: Ophthalmic Glaucoma Agents Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Ophthalmic Glaucoma Agents Month/Year

More information

Medical Treatment in Pediatric Glaucoma

Medical Treatment in Pediatric Glaucoma Medical Treatment in Pediatric Glaucoma By Nader Bayoumi, MD Lecturer of Ophthalmology Ophthalmology Department Alexandria University Alexandria, Egypt ESG 2012 Pediatric glaucoma is a surgical disease

More information

Understanding and Living with Glaucoma

Understanding and Living with Glaucoma Understanding and Living with Glaucoma Amanda hopes future generations won t have to live with glaucoma. Dr. Dubra s breakthrough research could mean they won t have to. I genuinely believe that a cure

More information

Chronicity. Narrow Minded. Course Outline. Acute angle closure. Subacute angle closure. Classification of Angle Closure 5/19/2014

Chronicity. Narrow Minded. Course Outline. Acute angle closure. Subacute angle closure. Classification of Angle Closure 5/19/2014 Chronicity Narrow Minded The management of narrow angles in the optometric practice Acute Subacute Chronic Aaron McNulty, OD, FAAO Course Outline Classification of Angle Closure Evaluation of narrow angles

More information

Definition & Classification

Definition & Classification Current Trends and Advances in Glaucoma Treatment in the U.S. and Other Countries 2015 JCAHPO ASCRS San Diego, CA., U.S.A. Saturday, April 18, 2015 Session B Dr. John T. Huang M.D., FRCSC, Dipl ABO Dr.

More information

BETAGAN Allergan Levobunolol HCl Glaucoma Therapy

BETAGAN Allergan Levobunolol HCl Glaucoma Therapy BETAGAN Allergan Levobunolol HCl Glaucoma Therapy Action And Clinical Pharmacology: Levobunolol is a noncardioselective beta- adrenoceptor antagonist, equipotent at both beta1 and beta2 receptors. Levobunolol

More information

PGAs. Glaucoma Pharmacology A-Z. Selecting Therapy. PGAs Prostaglandin analogs. Prostaglandin Side Effects 1/6/2014

PGAs. Glaucoma Pharmacology A-Z. Selecting Therapy. PGAs Prostaglandin analogs. Prostaglandin Side Effects 1/6/2014 PGAs Glaucoma Pharmacology A-Z Eric E. Schmidt, O.D. Omni Eye Specialists Wilmington, NC schmidtyvision@msn.com QHS dosing Long duration of action Flatten diurnal curve Effective on trough and peak IOP

More information

An hour behind schedule, the waiting room is

An hour behind schedule, the waiting room is Key Technical Skills I Checked the Intraocular Pressure. Now What Do I Do? KEY TECHNICAL SKILLS By Janet Hunter, bs, comt An hour behind schedule, the waiting room is packed with anxious patients, and

More information

11/30/2009. Glaukosis: ancient greek term meaning sparkling or shining appearance of pupil

11/30/2009. Glaukosis: ancient greek term meaning sparkling or shining appearance of pupil Normal Ocular Anatomy Glaucoma Dr Sunil Deokule, MD Asst. Prof and Glaucoma Specialist University of Kentucky Definition Glaukosis: ancient greek term meaning sparkling or shining appearance of pupil Optic

More information

Present relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS.

Present relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS. Course title: The Glaucoma Compass Course length: 1 hour +/- 31 slides Corse Description: Even with the technology and available information, glaucoma decision making can still be confusing. How should

More information

EXAMINING PATIENT-PHYSICIAN COMMUNICATION REGARDING COST IN THE GLAUCOMA PATIENT POPULATION

EXAMINING PATIENT-PHYSICIAN COMMUNICATION REGARDING COST IN THE GLAUCOMA PATIENT POPULATION EXAMINING PATIENT-PHYSICIAN COMMUNICATION REGARDING COST IN THE GLAUCOMA PATIENT POPULATION Catherine Slota A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in

More information

Reducing the Pressure on Glaucoma Decision-Making

Reducing the Pressure on Glaucoma Decision-Making Reducing the Pressure on Glaucoma Decision-Making Ron Melton, OD, FAAO Randall Thomas, OD, MPH, FAAO www.eyeupdate.com Financial Disclosure Dr. Ron Melton and Dr. Randall Thomas are consultants to, on

More information

DIRECT REFERRAL OF CATARACT PATIENTS COMMUNITY OPTOMETRIST PROTOCOL AND GUIDELINES

DIRECT REFERRAL OF CATARACT PATIENTS COMMUNITY OPTOMETRIST PROTOCOL AND GUIDELINES DIRECT REFERRAL OF CATARACT PATIENTS COMMUNITY OPTOMETRIST PROTOCOL AND GUIDELINES October 2013 Preoperative assessment History Symptoms/social history: is the patient visually affected and do they want

More information

NICE guideline Published: 1 November 2017 nice.org.uk/guidance/ng81

NICE guideline Published: 1 November 2017 nice.org.uk/guidance/ng81 Glaucoma: diagnosis and management NICE guideline Published: 1 November 2017 nice.org.uk/guidance/ng81 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Plateau Iris Therapeutic options and functional results after treatment

Plateau Iris Therapeutic options and functional results after treatment Romanian Journal of Ophthalmology, Volume 61, Issue 2, April-June 2017. pp:117-122 GENERAL ARTICLE Plateau Iris Therapeutic options and functional results after treatment Feraru Crenguța* **, Bâlha Andrei**,

More information

Ophthalmology Unit Referral Guidelines

Ophthalmology Unit Referral Guidelines Ophthalmology Unit Referral Guidelines Austin Health Ophthalmology Unit holds sub-specialty sessions to discuss and plan the treatment of patients with specific ocular conditions. General including cataract

More information

One-year Results of a Schlemm s Canal Microstent for IOP Reduction in Open Angle Glaucoma

One-year Results of a Schlemm s Canal Microstent for IOP Reduction in Open Angle Glaucoma One-year Results of a Schlemm s Canal Microstent for IOP Reduction in Open Angle Glaucoma Thomas W. Samuelson, MD Minnesota Eye Consultants On Behalf of the HYDRUS I Investigators 1 Disclosures This study

More information

Glaucoma What You Should Know

Glaucoma What You Should Know Glaucoma What You Should Know U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute The National Eye Institute (NEI) conducts and supports research that leads

More information

Ocular Manifestations of Systemic Disease: Grand Rounds Kimberly K. Reed, O.D., FAAO

Ocular Manifestations of Systemic Disease: Grand Rounds Kimberly K. Reed, O.D., FAAO Ocular Manifestations of Systemic Disease: Grand Rounds Kimberly K. Reed, O.D., FAAO Course description: This course describes several ocular presentations that result from a systemic disease or condition.

More information

Mild NPDR. Moderate NPDR. Severe NPDR

Mild NPDR. Moderate NPDR. Severe NPDR Diabetic retinopathy Diabetic retinopathy is the most common cause of blindness in adults aged 35-65 years-old. Hyperglycaemia is thought to cause increased retinal blood flow and abnormal metabolism in

More information

How Strongly Do You Feel That This Patient Has Glaucoma? % % % % %

How Strongly Do You Feel That This Patient Has Glaucoma? % % % % % My Favorite Cases Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, Maryland Dr. Litwak is a speaker and on advisory boards for Alcon and Zeiss Meditek CASE CR 35 yohf Neg PMH +FOH mother and grandmother

More information

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Medical Retina November 2016 Association of Health Professions in Ophthalmology General basic

More information

VN 122 MODULE F EYE AND VISION DISORDERS OCULAR HISTORY 1. PATIENT PERCEPTION OF PROBLEM 2. DECREASED VISION? 3. BLURRED, DOUBLE, DISTORTED?

VN 122 MODULE F EYE AND VISION DISORDERS OCULAR HISTORY 1. PATIENT PERCEPTION OF PROBLEM 2. DECREASED VISION? 3. BLURRED, DOUBLE, DISTORTED? VN 122 MODULE F EYE AND VISION DISORDERS OCULAR HISTORY 1. PATIENT PERCEPTION OF PROBLEM 2. DECREASED VISION? 3. BLURRED, DOUBLE, DISTORTED? 4. PAIN? QUALITY OF PAIN? 5. ITCHING, DRY? 6. BOTH EYES? 7.

More information

Primary Open Angle Glaucoma (POAG) Primary Angle Closure Glaucoma (PACG) _ acute _ chronic Other causes of glaucoma (secondary glaucoma)

Primary Open Angle Glaucoma (POAG) Primary Angle Closure Glaucoma (PACG) _ acute _ chronic Other causes of glaucoma (secondary glaucoma) T H E M E : E Y E RECENT ADVANCES IN GLAUCOMA MANAGEMENT Dr VKY Yong, Dr PTK Chew INTRODUCTION Definition Glaucoma describes a group of heterogenous disorders in which progressive damage to the optic nerve

More information

Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study

Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study James H. Peace, M.D. 1, Casey K. Kopczynski, Ph.D. 2, and Theresa Heah, M.D. 2 1 Inglewood, CA 2

More information

PHAR763: Pathophysiology and Therapeutics Ophthalmic Disorders: Glaucoma June 4, Julianne E. Himstreet, Pharm.D., BCPS

PHAR763: Pathophysiology and Therapeutics Ophthalmic Disorders: Glaucoma June 4, Julianne E. Himstreet, Pharm.D., BCPS PHAR763: Pathophysiology and Therapeutics Ophthalmic Disorders: Glaucoma June 4, 2008 Julianne E. Himstreet, Pharm.D., BCPS Recommended Reading: Applied Therapeutics Chapter 51. I. Learning Objectives

More information

GENERAL INFORMATION GLAUCOMA GLAUCOMA

GENERAL INFORMATION GLAUCOMA GLAUCOMA GENERAL INFORMATION GLAUCOMA GLAUCOMA WHAT IS GLAUCOMA? Glaucoma is commonly known as the sneak thief of sight because it can cause irreversible vision loss without any obvious symptoms. The term glaucoma

More information

My Favourite Cases Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD

My Favourite Cases Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD My Favourite Cases Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD Dr. Litwak is a speaker and on advisory boards for Alcon and Zeiss Meditek CASE CR! 35 YOHF! Neg PMH! +FOH mother and grandmother

More information

Glaucoma. Glaucoma. Glaucoma. Trevor Arnold, MS, DVM, DACVO

Glaucoma. Glaucoma. Glaucoma. Trevor Arnold, MS, DVM, DACVO Glaucoma Trevor Arnold, MS, DVM, DACVO Glaucoma Physiology of Aqueous Humor Produced in the ciliary body Flows out the iridocorneal angle and ciliary cleft High intraocular pressures are caused by a decreased

More information

Laser Learning Workshop: What Every Optometrist Needs to Know

Laser Learning Workshop: What Every Optometrist Needs to Know Laser Learning Workshop: What Every Optometrist Needs to Know Nate Lighthizer, O.D., F.A.A.O. Assistant Professor, NSUOCO Assistant Dean, Clinical Care Services Director of CE Chief of Specialty Care Clinics

More information

PRESCRIBING IN GLAUCOMA: GUIDELINES FOR NZ OPTOMETRISTS

PRESCRIBING IN GLAUCOMA: GUIDELINES FOR NZ OPTOMETRISTS PRESCRIBING IN GLAUCOMA: GUIDELINES FOR NZ OPTOMETRISTS Introduction Independent prescribing relates to the capacity to use clinical judgement in respect of diagnosis and treatment. It does not mean working

More information

Retinal Detachment PATIENT EDUCATION

Retinal Detachment PATIENT EDUCATION Retinal Detachment PATIENT EDUCATION What is Retinal Detachment (RD)? Retina is the light-sensitive layer at the back of the eye that converts light images into nerve impulses that are relayed to the brain

More information

Continuing Education

Continuing Education Continuing Education Glaucoma: Overview & Treatment Options Authors: Tyler Rinker, Pharm.D. Harrison School of Pharmacy, Auburn University Mary Elizabeth Terrell, Pharm.D. Harrison School of Pharmacy,

More information

Clinical Guidance and Monitoring for Change. Cecilia Fenerty MD FRCOphth Manchester Royal Eye Hospital

Clinical Guidance and Monitoring for Change. Cecilia Fenerty MD FRCOphth Manchester Royal Eye Hospital Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth Manchester Royal Eye Hospital Glaucoma Referral Criteria 2000 Original referral scheme Simple criteria based on IOP/Disc/Field Solitary

More information

Glaucoma: Diagnostic Modalities

Glaucoma: Diagnostic Modalities Glaucoma: Diagnostic Modalities - Dr. Barun Kumar Nayak, Dr. Sarika Ramugade Glaucoma is a leading cause of blindness in the world, especially in older people. Early detection and treatment by ophthalmologist

More information

Behandlungsstrategien beim Offenwinkelglaukom. F. Bochmann, Augenklinik LUKS

Behandlungsstrategien beim Offenwinkelglaukom. F. Bochmann, Augenklinik LUKS Behandlungsstrategien beim Offenwinkelglaukom F. Bochmann, Augenklinik LUKS What is strategy? what is our goal? where are we? how can we achieve our goal? Mission Statement The goal of glaucoma management

More information

Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist

Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions

More information

A complicated groups of disorders characterized by optic disc and v. field changes related to a high or a statically normal IOP. It involves a study

A complicated groups of disorders characterized by optic disc and v. field changes related to a high or a statically normal IOP. It involves a study THE GLAUCOMAS A complicated groups of disorders characterized by optic disc and v. field changes related to a high or a statically normal IOP. It involves a study of (1) IOP(2) ON head changes (3) V.field

More information

Diabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

Diabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Diabetic Retinopathy Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Outline Statistics Anatomy Categories Assessment Management Risk factors What do you need to do? Objectives Summarize the

More information

Gas for Vitreomacular Traction RCT (Protocol AG) Gas for Macular Hole Single-Arm Study (Protocol AH)

Gas for Vitreomacular Traction RCT (Protocol AG) Gas for Macular Hole Single-Arm Study (Protocol AH) Gas for Vitreomacular Traction RCT (Protocol AG) Gas for Macular Hole Single-Arm Study (Protocol AH) Protocol AG Chair: Clement Chan, MD Protocol AH Chair: Calvin Mein, MD DRCR.net Protocol AG Randomized

More information

Long-term outcome after cataract extraction in patients with an attack of acute phacomorphic angle closure

Long-term outcome after cataract extraction in patients with an attack of acute phacomorphic angle closure ORIGINAL ARTICLE Long-term outcome after cataract extraction in patients with an attack of acute phacomorphic angle closure Jimmy S. M. Lai, 1 FRCS, FRCOphth, FHKAM (Ophthalmology), M.Med (Ophthalmology),

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Conversion of Ocular Hypertensives into Glaucoma: A Retrospective Study Aditi Singh 1, Shibi

More information

Romanian Journal of Ophthalmology, Volume 59, Issue 3, July-September pp:

Romanian Journal of Ophthalmology, Volume 59, Issue 3, July-September pp: Romanian Journal of Ophthalmology, Volume 59, Issue 3, July-September 2015. pp:148-153 GENERAL ARTICLE SELECTIVE LASER TRABECULOPLASTY SHORT TERM EFFICACY AND SAFETY PROFILE IN OPEN ANGLE GLAUCOMA OR OCULAR

More information

Coexisting Cataract with Glaucoma & Role of Phacotrabeculectomy. Dr Mudit Agrawal

Coexisting Cataract with Glaucoma & Role of Phacotrabeculectomy. Dr Mudit Agrawal Coexisting Cataract with Glaucoma & Role of Phacotrabeculectomy Dr Mudit Agrawal Glaucoma and cataract often occur together,especially in elderly and each condition can influence management of the other.

More information